On Jul. 14, 2023, Gilead Sciences announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental new drug application for the use of Veklury (remdesivir) in COVID-19 patients with severe renal impairment, including those on dialysis. With this approval, Veklury was the first and only approved antiviral COVID-19 treatment that can be used across all stages of renal disease.

In the United States, Veklury is indicated for the treatment of COVID-19 in adults and pediatric patients (28 days and older and weighing at least 3 kg) who are either hospitalized, or not hospitalized and are at high risk for progression to severe COVID-19, including hospitalization or death. Veklury is contraindicated in patients who are allergic to Veklury or any of its components; please see below for additional Important Safety Information for Veklury.

More than 1 in 7 (37 million) people in the U.S. are estimated to have chronic kidney disease and are at increased risk of COVID-19 related morbidity and mortality.